MNI BRIEF: Japan Q1 GDP To Fall 0.4% Q/Q; Annualised -1.6%

MNI BRIEF: Canada Opposition Leader Removed From Legislature

CANADA Q1 FLASH ANNUALIZED GDP +2.5%, +0.6% QOQ

MNI WATCH: CNB Seen Cutting 50Bps to 5.25%, Signal Slower Pace

MNI China Daily Summary: Tuesday, April 30

MNI BRIEF: China To Keep Tackling Risks In Real Estate, Debts

US MBA: REFIS -3% SA; PURCH INDEX -2% SA THRU APRIL 26 WK

MNI: US MBA: MARKET COMPOSITE -2.3% SA THRU APR 26 WK

Small upward revision to UK manufacturing PMI; little market impact

RPT-MNI: Canada Sticks To Fiscal Anchors, Spends Chunk Of Windfall

MNI BRIEF: Poilievre Calls QE 'Scam' And Would Limit BOC Remit

MNI: Growth Drag From Net Zero Carbon Goal Can Be Offset-OECD

© 1982-2023 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

Sartorius (SRTGR; NR, BBB S) {SRT GR Equity} 1Q24 Earnings

HEALTHCARE
Credit BulletsBulletHomepagemarkets-real-timeCredit

Our view on cash lines are tad more bearish after earnings call comments with mgmt indicating acquisitions even this year were possible & seemed to imply low 3x's on leverage was satisfactory as a target (vs. stated 2-3x). We don't see issues with the 26's but further out lines do not screen cheap to us here given uncertainty ahead.

  • Equities including its 70% owned subsidiary {DIM FP Equity} are heading for a rough close - its not coming from highs & its fall did have flow through to lab services/equipment sector; {BIO US Equity} {BRKR US Equity} {WAT US Equity} {TMO US Equity}
  • Cash lines are more mute +5-6bps wider - moves we were fine with this morning but earnings call comments did flash red for us. As we mentioned operating performance recovery this year remains at the peril of mgmt guidance playing out - analyst (large coverage) was in line with it heading into earnings.
  • Leverage moved in the right direction & guidance for it in the low 3x's by year end is firm/better than previous guidance (for 4x). Our concern is M&A - tone in Q&A seemed to indicate appetite is there even this year - likely to see rating pressure if it does. It also said its happy with leverage target...slightly above 3 (current ratings were against target 2-3x) & also indicated deleveraging would be without any additional capital measures (i.e. equity raises).
  • The 26s still screen fair to cheap on a liquidity play; its buffed up cash now at €1b after equity raises & is against €300m in current liabilities. We see ~€500m in debt ahead of the 26's - most in SSD's.
275 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Our view on cash lines are tad more bearish after earnings call comments with mgmt indicating acquisitions even this year were possible & seemed to imply low 3x's on leverage was satisfactory as a target (vs. stated 2-3x). We don't see issues with the 26's but further out lines do not screen cheap to us here given uncertainty ahead.

  • Equities including its 70% owned subsidiary {DIM FP Equity} are heading for a rough close - its not coming from highs & its fall did have flow through to lab services/equipment sector; {BIO US Equity} {BRKR US Equity} {WAT US Equity} {TMO US Equity}
  • Cash lines are more mute +5-6bps wider - moves we were fine with this morning but earnings call comments did flash red for us. As we mentioned operating performance recovery this year remains at the peril of mgmt guidance playing out - analyst (large coverage) was in line with it heading into earnings.
  • Leverage moved in the right direction & guidance for it in the low 3x's by year end is firm/better than previous guidance (for 4x). Our concern is M&A - tone in Q&A seemed to indicate appetite is there even this year - likely to see rating pressure if it does. It also said its happy with leverage target...slightly above 3 (current ratings were against target 2-3x) & also indicated deleveraging would be without any additional capital measures (i.e. equity raises).
  • The 26s still screen fair to cheap on a liquidity play; its buffed up cash now at €1b after equity raises & is against €300m in current liabilities. We see ~€500m in debt ahead of the 26's - most in SSD's.